GlobalData: Diagnosed prevalent cases of diabetic macular edema (DME) to reach 3.46 million in 2034
The diagnosed prevalent cases of diabetic macular edema (DME) in the diabetes population across the seven major markets (7MM*) are expected to increase at an annual growth rate (AGR) of 1.99% from 2.89 million in 2024 to 3.46 million in 2034, forecasts GlobalData, a leading data and analytics company.
GlobalData’s report, “Diabetic Macular Edema (DME) – Epidemiology Forecast to 2034,” reveals that the US will have the highest number of diagnosed prevalent cases of DME in diabetes among the 7MM at 1.01 million, whereas Japan will have the lowest number at 0.13 million cases in 2034.
Antara Bhattacharya, Associate Project Manager, Epidemiology at GlobalData, comments: “In 2024, the disease burden in the 7MM showed a clear gender skew, with men accounting for around 57% of cases compared with 43% among women.”
Adults in ages 50 years and above accounted for slightly higher than 84% of the diagnosed prevalent cases of DME in diabetes in the 7MM in 2024, while comparatively younger adults in ages 20-49 years accounted for approximately 16% of the cases.
GlobalData estimates that in 2024, approximately 81% of diagnosed prevalent cases of DME in diabetes were center involving or ci-DME, whereas only 19% of diagnosed prevalent cases of DME in diabetes were non-center involving or nci-DME.
Bhattacharya concludes: “Globally, DME represents the major cause of vision impairment in diabetic patients with an increasing prevalence. The disease management is challenging due to difficulty in early detection, proper management of blood sugar and/or blood pressure levels, risk of severe, irreversible vision loss, and concurrent conditions such as kidney disease. Additionally, effective treatment requires frequent, long-term administration.
“Research based approach by working with a medical team on treatment and disease management and adopting lifestyle changes and coping strategies for reduced vision can extend our understanding of the disease.”
*7MM: The US, 5EU (France, Germany, Italy, Spain, the UK), and Japan.
Source: GlobalData